VOLUME 26, ISSUE 1 • March 2022. Full issue »
The First MDCP Conference on Unanswered Questions and Unsolved Issues in Clinical Practice
Share this: Tweet
With more than 1,500 registered participants the first MDCP meeting on unanswered questions and unsolved issues in Clinical Practice was held in November in a virtual format. The meeting was celebrated after the journal was formally accepted to Clarivate’s Science Citation Index Expanded (SCIE). MDCP will receive its first impact factor in June 2022.
MDCP began accepting submissions in late 2013 and published its first issue in January 2014. We initially published on a quarterly basis but grew to six issues in 2016 and then ten issues in 2019. Due to growing demand from authors and readers alike, we intend to expand to a monthly publication beginning in 2023.
Since its inception, MDCP has considered the clinical neurologist—at all stages of their career—as its main audience. Perhaps the best definition of MDCP is highlighted by a comment made by a leading clinician in the field who stated “MDCP is the journal that doctors who see patients read”. In line with this, in addition to the video supported material, educational reviews, videos from experts in the ‘How do I” section as well as the recent new addition of genotype-phenotype letters, we took a further step forward to promoting debate and discussion between recognized clinical specialist in the Movement Disorders field in this virtual meeting.
The meeting was focused on the unanswered questions and unmet needs in the field of movement disorders. Obviously, we could not cover every issue, but topics were carefully selected for presentations focusing on areas which are issues in clinical practice.
Faculty from the first MDCP conference.
The program was heterogeneous reflecting itself the unanswered questions and unmet needs in practice and therefore it was difficult to structure the sessions under a specific topic. The first day covered topics ranging from advances in genetics, biomarkers, and antibodies to the off-label use of drugs and the new classification of tremor. The second day was also varied and included issues from ICD, gait, and L-dopa nonresponsive symptoms to functional movement disorders and the utility of instrumental technology to evaluate movement disorders. Discussions were led by chairpersons and were often animated and intense.
However, we did feel as the meeting progressed that perhaps the time offered for discussion was relatively limited and in the future longer discussion could be planned. As always, one learns from one’s experiences. Based on the lessons learned from this first conference, we may consider a “non-lecture” format for the next meeting, with only discussions by experts with informed and challenging moderators.
The proceedings of the full conference will be available as an open access virtual video supplement during 2022 and edited discussions will also be published in a viewpoint format covering all the sessions of the meeting.
The success of MDCP and its recently meeting would not be possible without the tremendous support from MDS, its leadership and its members who are an indefatigable source of reviewers and authors. We also thank the large number of dedicated MDS staff earmarked for this event and working behind the scenes to make it the success it was.
View the panel videos:
Day 1 – Panel Discussion 1
Day 1 – Panel Discussion 2
Day 2 – Panel Discussion 1
Day 2 – Panel Discussion 2
Share this: Tweet
Read more Moving Along: